Selected stock price target news of the day - March 27th, 2025

By: Matthew Otto

Nkarta Restructures to Extend Cash Runway as NKX019 Trials Advance

As of December 31, 2024, Nkarta reported a cash balance of $380.5 million, inclusive of cash, cash equivalents, and investments, which is projected to sustain operations into 2029. Research and development (R&D) expenses totaled $96.7 million for the year, with $23.1 million allocated in the fourth quarter. General and administrative (G&A) expenses for the year amounted to $31.5 million, while fourth-quarter G&A costs were $7.8 million. Nkarta reported a net loss of $108.8 million for the year, translating to a loss of $1.60 per share, with a fourth-quarter net loss of $25.9 million or $0.35 per share.

Nkarta announced a restructuring plan, including a 34% reduction in its workforce (53 positions) and a hiring freeze on select future roles. This initiative aims to extend the cash runway by over a year while ensuring continued investment in key clinical programs. Cash payments related to the restructuring are estimated between $5.5 million and $6.5 million. Nkarta has also harmonized the dosing schedule for NKX019 across all four clinical trials, administering three doses on Days 0, 3, and 7 following single-agent lymphodepletion with cyclophosphamide.

Analysts Reaffirm Buy Ratings While Adjusting Price Targets

Stifel analyst Stephen Willey maintained a Buy rating and lowered the price target from $15 to $14.
Needham analyst Gil Blum reiterated a Buy rating and the price target at $11.
HC Wainwright & Co. analyst Emily Bodnar reaffirmed a Buy rating and the price target at $18.

Which Analyst has the best track record to show on NKTX?

Analyst Salim Syed (MIZUHO) currently has the highest performing score on NKTX with 3/5 (60%) price target fulfillment ratio. His price targets carry an average of $17.78 (134.49%) potential upside. Nkarta stock price reaches these price targets on average within 32 days.

Cintas Reports Q3 FY25 Earnings, Beats EPS Estimates, and Raises Guidance

Cintas reported fiscal 2025 third-quarter revenue of $2.61 billion, an 8.4% increase from $2.41 billion in the prior-year quarter, slightly surpassing the consensus estimate of $2.6 billion. Organic revenue growth, which excludes acquisitions and foreign currency impacts, was 7.9%.

Gross margin rose 11.1% to $1.32 billion, representing 50.6% of revenue, up from 49.4% last year. Operating income increased 17.1% to $609.9 million, with an operating margin of 23.4%, compared to 21.6% in the previous year. Net income was $463.5 million, up 16.6% from $397.6 million. Diluted EPS grew 17.7% to $1.13, exceeding analyst expectations of $1.05 by $0.08. The effective tax rate for the quarter was 21.0%, compared to 19.9% last year.

Cintas updated its fiscal 2025 guidance, raising diluted EPS expectations from a range of $4.28 to $4.34 to $4.36 to $4.40, above the consensus estimate of $4.33. Revenue guidance was adjusted to a range of $10.280 billion to $10.305 billion, slightly below the consensus estimate of $10.32 billion. Organic revenue growth expectations were raised to a range of 7.4% to 7.7%, up from a prior low-end estimate of 7.0%.

Analysts Adjust Price Targets Following Q3 Results

Baird analyst Andrew Wittmann maintained a Neutral rating while raising the price target from $200 to $227.
Wells Fargo analyst Jason Haas kept an Underweight rating yet lifted the price target from $184 to $196.
UBS analyst Joshua Chan reiterated a Buy rating and increased the price target from $218 to $240.

Which Analyst has the best track record to show on CTAS?

Analyst Shlomo Rosenbaum (STIFEL) currently has the highest performing score on CTAS with 11/12 (91.67%) price target fulfillment ratio. His price targets carry an average of $6.56 (3.60%) potential upside. Cintas stock price reaches these price targets on average within 60 days.

Chewy Reports Fiscal Q4 and Full-Year 2024 Results, Provides Q1 and FY26 Outlook

Chewy announced its financial results for the fiscal fourth quarter and full year 2024. In Q4 2024, net sales increased 14.9% year over year to $3.25 billion, while gross margin expanded by 30 basis points to 28.5%. Adjusted EBITDA rose by $38.1 million to $124.5 million, representing a margin expansion of 70 basis points to 3.8%. However, net margin declined 40 basis points to 0.7%, with net income at $22.8 million.

Basic and diluted earnings per share (EPS) came in at $0.06 and $0.05, respectively, reflecting slight declines from the prior year. Adjusted net income grew $39.7 million to $120.0 million, with adjusted basic and diluted EPS increasing by $0.10 each to $0.29 and $0.28, respectively.

For the full fiscal year 2024, Chewy posted net sales of $11.86 billion, marking a 6.4% year-over-year increase. Gross margin improved by 80 basis points to 29.2%, while net income reached $392.7 million. Net margin expanded by 290 basis points to 3.3%, and adjusted EBITDA climbed by $202.5 million to $570.5 million, with a 150-basis-point increase in adjusted EBITDA margin to 4.8%.Basic EPS rose by $0.84 to $0.93, and diluted EPS increased by $0.82 to $0.91. Adjusted net income reached $446.8 million, a $150.6 million increase from the prior year, with adjusted basic and diluted EPS growing by $0.37 and $0.35, respectively, to $1.06 and $1.04.

Looking ahead, Chewy expects Q1 2025 EPS in the range of $0.30 to $0.35, compared to the consensus estimate of $0.33. First-quarter revenue guidance of $3.06 billion to $3.09 billion exceeds the consensus estimate of $3.04 billion. For fiscal year 2026, Chewy projects revenue between $12.3 billion and $12.45 billion, slightly below the consensus estimate of $12.43 billion at the midpoint.

Analysts Adjust Price Targets Following Q4 and FY24 Results

Barclays analyst Trevor Young maintained an Overweight rating and raised the price target from $40 to $44.
Needham analyst Bernie McTernan reiterated a Hold rating.
UBS analyst Michael Lasser raised the price target from $34 to $36.
Goldman Sachs analyst Alexandra Steiger lowered the price target from $45 to $40.
Citi analyst Steven Zaccone raised the price target from $40 to $42.
Wedbush analyst Seth Basham reiterated an Outperform rating and a $39 price target.

Which Analyst has the best track record to show on CHWY?

Analyst Peter Keith (PIPER SANDLER) currently has the highest performing score on CHWY with 9/12 (75%) price target fulfillment ratio. His price targets carry an average of $6.37 (18.94%) potential upside. Chewy stock price reaches these price targets on average within 57 days.